Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges

Identification of the cystic fibrosis transmembrane conductance regulator<i> (CFTR)</i> gene and its numerous variants opened the way to fantastic breakthroughs in diagnosis, research and treatment of cystic fibrosis (CF). The current and future challenges of molecular diagnosis of CF an...

Full description

Bibliographic Details
Main Authors: Thierry Bienvenu, Maureen Lopez, Emmanuelle Girodon
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Genes
Subjects:
Online Access:https://www.mdpi.com/2073-4425/11/6/619
id doaj-10eb7e34feb14b5fa8f571418557601f
record_format Article
spelling doaj-10eb7e34feb14b5fa8f571418557601f2020-11-25T03:11:28ZengMDPI AGGenes2073-44252020-06-011161961910.3390/genes11060619Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New ChallengesThierry Bienvenu0Maureen Lopez1Emmanuelle Girodon2Molecular Genetics Laboratory, Cochin Hospital, APHP.Centre–Université de Paris, 75014 Paris, FranceMolecular Genetics Laboratory, Cochin Hospital, APHP.Centre–Université de Paris, 75014 Paris, FranceMolecular Genetics Laboratory, Cochin Hospital, APHP.Centre–Université de Paris, 75014 Paris, FranceIdentification of the cystic fibrosis transmembrane conductance regulator<i> (CFTR)</i> gene and its numerous variants opened the way to fantastic breakthroughs in diagnosis, research and treatment of cystic fibrosis (CF). The current and future challenges of molecular diagnosis of CF and CFTR-related disorders and of genetic counseling are here reviewed. Technological advances have enabled to make a diagnosis of CF with a sensitivity of 99% by using next generation sequencing in a single step. The detection of heretofore unidentified variants and ethnic-specific variants remains challenging, especially for newborn screening (NBS), CF carrier testing and genotype-guided therapy. Among the criteria for assessing the impact of variants, population genetics data are insufficiently taken into account and the penetrance of CF associated with <i>CFTR</i> variants remains poorly known. The huge diversity of diagnostic and genetic counseling indications for <i>CFTR</i> studies makes assessment of variant disease-liability critical. This is especially discussed in the perspective of wide genome analyses for NBS and CF carrier screening in the general population, as future challenges.https://www.mdpi.com/2073-4425/11/6/619cystic fibrosisCFTRCFTR-related disordersmolecular diagnosisCFTR variantsNext Generation Sequencing (NGS)
collection DOAJ
language English
format Article
sources DOAJ
author Thierry Bienvenu
Maureen Lopez
Emmanuelle Girodon
spellingShingle Thierry Bienvenu
Maureen Lopez
Emmanuelle Girodon
Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges
Genes
cystic fibrosis
CFTR
CFTR-related disorders
molecular diagnosis
CFTR variants
Next Generation Sequencing (NGS)
author_facet Thierry Bienvenu
Maureen Lopez
Emmanuelle Girodon
author_sort Thierry Bienvenu
title Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges
title_short Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges
title_full Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges
title_fullStr Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges
title_full_unstemmed Molecular Diagnosis and Genetic Counseling of Cystic Fibrosis and Related Disorders: New Challenges
title_sort molecular diagnosis and genetic counseling of cystic fibrosis and related disorders: new challenges
publisher MDPI AG
series Genes
issn 2073-4425
publishDate 2020-06-01
description Identification of the cystic fibrosis transmembrane conductance regulator<i> (CFTR)</i> gene and its numerous variants opened the way to fantastic breakthroughs in diagnosis, research and treatment of cystic fibrosis (CF). The current and future challenges of molecular diagnosis of CF and CFTR-related disorders and of genetic counseling are here reviewed. Technological advances have enabled to make a diagnosis of CF with a sensitivity of 99% by using next generation sequencing in a single step. The detection of heretofore unidentified variants and ethnic-specific variants remains challenging, especially for newborn screening (NBS), CF carrier testing and genotype-guided therapy. Among the criteria for assessing the impact of variants, population genetics data are insufficiently taken into account and the penetrance of CF associated with <i>CFTR</i> variants remains poorly known. The huge diversity of diagnostic and genetic counseling indications for <i>CFTR</i> studies makes assessment of variant disease-liability critical. This is especially discussed in the perspective of wide genome analyses for NBS and CF carrier screening in the general population, as future challenges.
topic cystic fibrosis
CFTR
CFTR-related disorders
molecular diagnosis
CFTR variants
Next Generation Sequencing (NGS)
url https://www.mdpi.com/2073-4425/11/6/619
work_keys_str_mv AT thierrybienvenu moleculardiagnosisandgeneticcounselingofcysticfibrosisandrelateddisordersnewchallenges
AT maureenlopez moleculardiagnosisandgeneticcounselingofcysticfibrosisandrelateddisordersnewchallenges
AT emmanuellegirodon moleculardiagnosisandgeneticcounselingofcysticfibrosisandrelateddisordersnewchallenges
_version_ 1724654057666117632